All In Biotech

Drug Trial Radar · NCT07623525

DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia

A Phase 1/2, First-in-Human, Multicenter, Ascending Single-Dose and Multi-Dose Study to Assess the Safety of DIAG723, a Novel Bispecific ALK-1 and BMPRII Agonist Antibody in Adult Patients With Hereditary Hemorrhagic Telangiectasia (DIAMOND Trial)

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

93

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Nov 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Diagonal Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT). The study consists of three parts: Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics. Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT to assess safety and preliminary efficacy. Part C (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT and concomitant pulmonary arterial hypertension to assess safety and exploratory clinical effects in this population. Participants will be randomized within each study part to receive DIAG723 or placebo. The study includes dose escalation in Part A and dose expansion in Parts B and C.

Conditions

  • Hereditary Hemorrhagic Telangiectasia
  • Pulmonary Arterial Hypertension

Interventions

  • DIAG723Biological

    Bispecific agonist monoclonal antibody targeting ALK-1 and BMPRII, administered subcutaneously as: Single ascending dose in Part A; Multiple doses (7 doses over 13 weeks) in Parts B and C

  • PlaceboOther

    Sterile normal saline (0.9% NaCl) administered subcutaneously in volumes matched to DIAG723 to maintain study blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part A (Single Dose)Time frame: From first dose through Day 28
  2. Incidence of Serious Adverse Events (SAEs) - Part A (Single Dose)Time frame: From first dose through Day 28
  3. Incidence of Dose-Limiting Toxicities (DLTs) - Part A (Single Dose)Time frame: From first dose through Day 28
  4. Number of participants with abnormal laboratory tests results - Part A (Single Dose)Time frame: Baseline through Day 28
  5. Number of participants with abnormal vital signs - Part A (Single Dose)Time frame: Baseline through Day 28
  6. Change from Baseline in Electrocardiogram (ECG) Parameters - Part A (Single Dose)Time frame: Baseline through Day 28
  7. Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
  8. Incidence of Serious Adverse Events (SAEs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
  9. Incidence of Dose-Limiting Toxicities (DLTs) - Part B (Multiple Dose)Time frame: From first dose through 28 days after final dose
  10. Number of participants with abnormal laboratory tests results - Part B (Multiple Dose)Time frame: Baseline through Week 15
  11. Number of participants with abnormal vital signs - Part B (Multiple Dose)Time frame: Baseline through Week 17
  12. Change from Baseline in Electrocardiogram (ECG) Parameters - Part B (Multiple Dose)Time frame: Baseline through Week 17
  13. Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
  14. Incidence of Serious Adverse Events (SAEs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
  15. Incidence of Dose-Limiting Toxicities (DLTs) - Part C (Multiple Dose, HHT with PAH)Time frame: From first dose through 28 days after final dose
  16. Number of participants with abnormal laboratory tests results - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 15
  17. Number of participants with abnormal vital signs - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 17
  18. Change from Baseline in Electrocardiogram (ECG) Parameters - Part C (Multiple Dose, HHT with PAH)Time frame: Baseline through Week 17

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Diagonal Investigational Site

    Camperdown, New South Wales, Australia · Not yet recruiting

  • Diagonal Investigational Site

    Randwick, New South Wales, Australia · Recruiting

  • Diagonal Investigational Site

    Herston, Queensland, Australia · Not yet recruiting

  • Diagonal Investigational Site

    Herston, Queensland, Australia · Withdrawn

  • Diagonal Investigational Site

    East Melbourne, Victoria, Australia · Recruiting

  • Diagonal Investigational Site

    Parkville, Victoria, Australia · Not yet recruiting

  • Diagonal Investigational Site

    West Perth, Western Australia, Australia · Not yet recruiting

  • Diagonal Investigational Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Diagonal Investigational Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Diagonal Investigational Site

    Laval, Quebec, Canada · Not yet recruiting

  • Diagonal Investigational Site

    Grafton, Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.